← Back
Standard Biotools
LAB · listed on Nasdaq · worth $291.29 million
$0.6000
−1.64% on Oct 26
15 insider buys in the last year, $14.44 million in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
184.6M shares
47% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought Standard Biotools stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
Casdin Partners Master Fund
Bought $9.84M on Nov 25, 2025 — 7,550,000 shares at $1.30, held through a trust or family, 11% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of Standard Biotools, newest first.
All reports
Every insider trade and SEC report we hold for Standard Biotools.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Dec 4, 2025BoughtCasdin Partners Master FundDec 4, 2025 · 10% owner+0.2%via a trust or family150,000 @ $1.45$217K
Dec 4, 2025BoughtCasdin Partners Master FundDec 4, 2025 · Traded Dec 3, 2025 · 10% owner+0.1%via a trust or family75,000 @ $1.44$108K
Dec 4, 2025BoughtCasdin Partners Master FundDec 4, 2025 · Traded Dec 2, 2025 · 10% owner+0.2%via a trust or family125,000 @ $1.42$177.5K
Nov 26, 2025BoughtCasdin Partners Master FundNov 26, 2025 · Traded Nov 25, 2025 · 10% owner+11%via a trust or family7,550,000 @ $1.30$9.84M
Nov 26, 2025BoughtCasdin Partners Master FundNov 26, 2025 · Traded Nov 24, 2025 · 10% owner+0.2%via a trust or family150,000 @ $1.43$214.9K
24 more with Pro →Analysts, earnings and news
Analysts' price target
$1.55 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26−$0.02 a share+$0.00
Q4 '25$0.07 a share+$0.09
Q3 '25−$0.04 a share−$0.02
Q2 '25−$0.04 a share+$0.00